Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes

Jong Dai Kim, Cheol Young Park, Kue Jeong Ahn, Jae Hyoung Cho, Kyung Mook Choi, Jun Goo Kang, Jae Hyeon Kim, Ki Young Lee, Byung Wan Lee, Ji Oh Mok, Min Kyong Moon, Joong Yeol Park, Sung Woo Park

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: We evaluated the prevalence of aspirin resistance and predictive factors for aspirin resistance in Korean type 2 diabetes patients. Approach and results: A total of 1045 type 2 diabetes patients from 11 hospitals who were taking aspirin (100mg/day for ≥2 weeks) and no other antiplatelet agents were studied to evaluate aspirin resistance. Aspirin resistance was measured in aspirin reaction units using VerifyNow®. Aspirin resistance was defined as ≥550 aspirin reaction units.Aspirin resistance was detected in 102 of the 1045 subjects (prevalence 9.8%). Aspirin resistance was associated with total cholesterol (P=0.013), LDL-cholesterol (P=0.028), and non-HDL cholesterol (P=0.008) concentrations in univariate analysis. In multivariate logistic regression analysis, only non-HDL cholesterol was associated with aspirin resistance in obese (BMI >25kg/m2) type 2 diabetes patients (adjusted odds ratio 3.55, 95% CI: 1.25-10.05, P=0.017). Conclusions: The prevalence of aspirin resistance in Korean type 2 diabetes patients is 9.8%. Non-HDL cholesterol is an independent risk factor for aspirin resistance, especially in obese type 2 diabetes patients.

Original languageEnglish
Pages (from-to)146-151
Number of pages6
JournalAtherosclerosis
Volume234
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Type 2 Diabetes Mellitus
Aspirin
Cholesterol
R Factors
Platelet Aggregation Inhibitors
LDL Cholesterol
Logistic Models
Odds Ratio
Regression Analysis

Keywords

  • Aspirin resistance
  • Atherogenic dyslipidemia
  • Diabetes
  • Non-HDL cholesterol

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes. / Kim, Jong Dai; Park, Cheol Young; Ahn, Kue Jeong; Cho, Jae Hyoung; Choi, Kyung Mook; Kang, Jun Goo; Kim, Jae Hyeon; Lee, Ki Young; Lee, Byung Wan; Mok, Ji Oh; Moon, Min Kyong; Park, Joong Yeol; Park, Sung Woo.

In: Atherosclerosis, Vol. 234, No. 1, 01.01.2014, p. 146-151.

Research output: Contribution to journalArticle

Kim, JD, Park, CY, Ahn, KJ, Cho, JH, Choi, KM, Kang, JG, Kim, JH, Lee, KY, Lee, BW, Mok, JO, Moon, MK, Park, JY & Park, SW 2014, 'Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes', Atherosclerosis, vol. 234, no. 1, pp. 146-151. https://doi.org/10.1016/j.atherosclerosis.2014.01.015
Kim, Jong Dai ; Park, Cheol Young ; Ahn, Kue Jeong ; Cho, Jae Hyoung ; Choi, Kyung Mook ; Kang, Jun Goo ; Kim, Jae Hyeon ; Lee, Ki Young ; Lee, Byung Wan ; Mok, Ji Oh ; Moon, Min Kyong ; Park, Joong Yeol ; Park, Sung Woo. / Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes. In: Atherosclerosis. 2014 ; Vol. 234, No. 1. pp. 146-151.
@article{9c14e16bcde74841a9676f09a3eab88e,
title = "Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes",
abstract = "Objective: We evaluated the prevalence of aspirin resistance and predictive factors for aspirin resistance in Korean type 2 diabetes patients. Approach and results: A total of 1045 type 2 diabetes patients from 11 hospitals who were taking aspirin (100mg/day for ≥2 weeks) and no other antiplatelet agents were studied to evaluate aspirin resistance. Aspirin resistance was measured in aspirin reaction units using VerifyNow{\circledR}. Aspirin resistance was defined as ≥550 aspirin reaction units.Aspirin resistance was detected in 102 of the 1045 subjects (prevalence 9.8{\%}). Aspirin resistance was associated with total cholesterol (P=0.013), LDL-cholesterol (P=0.028), and non-HDL cholesterol (P=0.008) concentrations in univariate analysis. In multivariate logistic regression analysis, only non-HDL cholesterol was associated with aspirin resistance in obese (BMI >25kg/m2) type 2 diabetes patients (adjusted odds ratio 3.55, 95{\%} CI: 1.25-10.05, P=0.017). Conclusions: The prevalence of aspirin resistance in Korean type 2 diabetes patients is 9.8{\%}. Non-HDL cholesterol is an independent risk factor for aspirin resistance, especially in obese type 2 diabetes patients.",
keywords = "Aspirin resistance, Atherogenic dyslipidemia, Diabetes, Non-HDL cholesterol",
author = "Kim, {Jong Dai} and Park, {Cheol Young} and Ahn, {Kue Jeong} and Cho, {Jae Hyoung} and Choi, {Kyung Mook} and Kang, {Jun Goo} and Kim, {Jae Hyeon} and Lee, {Ki Young} and Lee, {Byung Wan} and Mok, {Ji Oh} and Moon, {Min Kyong} and Park, {Joong Yeol} and Park, {Sung Woo}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.atherosclerosis.2014.01.015",
language = "English",
volume = "234",
pages = "146--151",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Non-HDL cholesterol is an independent risk factor for aspirin resistance in obese patients with type 2 diabetes

AU - Kim, Jong Dai

AU - Park, Cheol Young

AU - Ahn, Kue Jeong

AU - Cho, Jae Hyoung

AU - Choi, Kyung Mook

AU - Kang, Jun Goo

AU - Kim, Jae Hyeon

AU - Lee, Ki Young

AU - Lee, Byung Wan

AU - Mok, Ji Oh

AU - Moon, Min Kyong

AU - Park, Joong Yeol

AU - Park, Sung Woo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective: We evaluated the prevalence of aspirin resistance and predictive factors for aspirin resistance in Korean type 2 diabetes patients. Approach and results: A total of 1045 type 2 diabetes patients from 11 hospitals who were taking aspirin (100mg/day for ≥2 weeks) and no other antiplatelet agents were studied to evaluate aspirin resistance. Aspirin resistance was measured in aspirin reaction units using VerifyNow®. Aspirin resistance was defined as ≥550 aspirin reaction units.Aspirin resistance was detected in 102 of the 1045 subjects (prevalence 9.8%). Aspirin resistance was associated with total cholesterol (P=0.013), LDL-cholesterol (P=0.028), and non-HDL cholesterol (P=0.008) concentrations in univariate analysis. In multivariate logistic regression analysis, only non-HDL cholesterol was associated with aspirin resistance in obese (BMI >25kg/m2) type 2 diabetes patients (adjusted odds ratio 3.55, 95% CI: 1.25-10.05, P=0.017). Conclusions: The prevalence of aspirin resistance in Korean type 2 diabetes patients is 9.8%. Non-HDL cholesterol is an independent risk factor for aspirin resistance, especially in obese type 2 diabetes patients.

AB - Objective: We evaluated the prevalence of aspirin resistance and predictive factors for aspirin resistance in Korean type 2 diabetes patients. Approach and results: A total of 1045 type 2 diabetes patients from 11 hospitals who were taking aspirin (100mg/day for ≥2 weeks) and no other antiplatelet agents were studied to evaluate aspirin resistance. Aspirin resistance was measured in aspirin reaction units using VerifyNow®. Aspirin resistance was defined as ≥550 aspirin reaction units.Aspirin resistance was detected in 102 of the 1045 subjects (prevalence 9.8%). Aspirin resistance was associated with total cholesterol (P=0.013), LDL-cholesterol (P=0.028), and non-HDL cholesterol (P=0.008) concentrations in univariate analysis. In multivariate logistic regression analysis, only non-HDL cholesterol was associated with aspirin resistance in obese (BMI >25kg/m2) type 2 diabetes patients (adjusted odds ratio 3.55, 95% CI: 1.25-10.05, P=0.017). Conclusions: The prevalence of aspirin resistance in Korean type 2 diabetes patients is 9.8%. Non-HDL cholesterol is an independent risk factor for aspirin resistance, especially in obese type 2 diabetes patients.

KW - Aspirin resistance

KW - Atherogenic dyslipidemia

KW - Diabetes

KW - Non-HDL cholesterol

UR - http://www.scopus.com/inward/record.url?scp=84897939773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897939773&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2014.01.015

DO - 10.1016/j.atherosclerosis.2014.01.015

M3 - Article

VL - 234

SP - 146

EP - 151

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -